Your Health, We Care
The most common adverse reactions (≥ 20%) were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory abnormalities (≥ 25%) were decreased lymphocytes, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urine protein, and decreased sodium.
from FDA，2023.04
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated ap···【more】
Release date：2026-03-23Recommended：40
Sotorasib is a targeted therapy drug directed against the KRAS G12C mutation, pr···【more】
Release date：2026-02-27Recommended：63
Sotorasibas a targeted therapeutic agent, is hailed as a milestone advancement i···【more】
Release date：2024-07-09Recommended：346
